CA2725008C — Non-hormonal steroid modulators of nf-.kappa.b for treatment of disease
Assigned to Reveragen Biopharma Inc · Expires 2017-09-05 · 9y expired
What this patent protects
The present invention relates to compounds and methods which may be useful as treatments of neuromuscular dis-eases such as muscular dystrophy, and as inhibitors of NF-.kappa.B for the treatment or prevention of muscular wasting disease, includ-ing muscular dystrophy.
USPTO Abstract
The present invention relates to compounds and methods which may be useful as treatments of neuromuscular dis-eases such as muscular dystrophy, and as inhibitors of NF-.kappa.B for the treatment or prevention of muscular wasting disease, includ-ing muscular dystrophy.
Drugs covered by this patent
- Agamree (VAMOROLONE) · Catalyst Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.